Compare GFAI & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GFAI | KLTOW |
|---|---|---|
| Founded | 2018 | N/A |
| Country | Singapore | United States |
| Employees | N/A | 3 |
| Industry | Diversified Commercial Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.4M | N/A |
| IPO Year | N/A | 2022 |
| Metric | GFAI | KLTOW |
|---|---|---|
| Price | $0.60 | $0.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 332.4K | N/A |
| Earning Date | 09-23-2025 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $36,987,715.00 | N/A |
| Revenue This Year | $5.66 | N/A |
| Revenue Next Year | $4.69 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.38 | N/A |
| 52 Week Low | $0.54 | N/A |
| 52 Week High | $2.20 | N/A |
| Indicator | GFAI | KLTOW |
|---|---|---|
| Relative Strength Index (RSI) | 36.79 | 44.85 |
| Support Level | $0.60 | $0.10 |
| Resistance Level | $0.80 | $0.11 |
| Average True Range (ATR) | 0.04 | 0.01 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 31.39 | 17.71 |
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, General Security Solutions, and Corporate and others. A majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.